UBS Group
VMD icon

UBS Group’s Viemed Healthcare VMD Stock Holding History

UBS Group’s Portfolio VMD Stock Details VMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$897K Sell
78,713
-139,095
-64% -$1.38M ﹤0.01% 5825
2026
Q1 		$2.01M Buy
217,808
+131,609
+153% +$1.1M ﹤0.01% 4973
2025
Q4 		$640K Sell
86,199
-87,212
-50% -$598K ﹤0.01% 5929
2025
Q3 		$1.18M Sell
173,411
-16,006
-8% -$108K ﹤0.01% 5425
2025
Q2 		$1.31M Buy
189,417
+93,132
+97% +$632K ﹤0.01% 5209
2025
Q1 		$701K Buy
96,285
+62,893
+188% +$494K ﹤0.01% 5584
2024
Q4 		$268K Buy
33,392
+16,109
+93% +$140K ﹤0.01% 6276
2024
Q3 		$127K Buy
17,283
+5,725
+50% +$40.9K ﹤0.01% 6190
2024
Q2 		$75.7K Sell
11,558
-25,885
-69% -$195K ﹤0.01% 6371
2024
Q1 		$353K Sell
37,443
-861
-2% -$7.38K ﹤0.01% 5455
2023
Q4 		$301K Buy
38,304
+19,910
+108% +$144K ﹤0.01% 5493
2023
Q3 		$124K Sell
18,394
-5,960
-24% -$48.8K ﹤0.01% 5690
2023
Q2 		$238K Buy
24,354
+20,063
+468% +$204K ﹤0.01% 5366
2023
Q1 		$41.5K Buy
4,291
+1,844
+75% +$16.1K ﹤0.01% 6585
2022
Q4 		$18.5K Buy
2,447
+1,590
+186% +$10.8K ﹤0.01% 7734
2022
Q3 		$5K Buy
+857
New +$5.5K ﹤0.01% 9234
2022
Q2 		– Sell
-5,174
Closed -$26K – 10993
2022
Q1 		$26K Sell
5,174
-10,386
-67% -$48.2K ﹤0.01% 7157
2021
Q4 		$81K Buy
+15,560
New +$86.8K ﹤0.01% 6494
2021
Q2 		– Sell
-11,096
Closed -$112K – 9856
2021
Q1 		$112K Sell
11,096
-5,801
-34% -$54.6K ﹤0.01% 5880
2020
Q4 		$131K Sell
16,897
-11,978
-41% -$105K ﹤0.01% 5516
2020
Q3 		$249K Buy
28,875
+15,126
+110% +$153K ﹤0.01% 4664
2020
Q2 		$132K Buy
13,749
+12,466
+972% +$96.9K ﹤0.01% 5103
2020
Q1 		$6K Sell
1,283
-727
-36% -$3.6K ﹤0.01% 7238
2019
Q4 		$12K Buy
+2,010
New +$13.9K ﹤0.01% 7198

Other funds holding VMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Forager Capital Management Birmingham, Alabama $266M AUM 40% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

UBS Group's VMD Position: Q2 2026 in Review

UBS Group reduced its Viemed Healthcare (VMD) stake by 64% in Q2 2026, selling an estimated $1.38M and leaving 78,713 shares worth $897K. The position accounts for ﹤0.01% of the portfolio, ranked #5825.

UBS Group first reported a position in VMD in Q4 2019 and has held it in 24 quarters since. The position peaked at $2.01M in Q1 2026. 166 funds tracked by Wall St. Rank hold VMD as of Q2 2026.

  • UBS Group held 78,713 shares of Viemed Healthcare worth $897K as of Q2 2026.
  • UBS Group sold 139,095 Viemed Healthcare shares in Q2 2026, an estimated $1.38M.
  • Viemed Healthcare made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5825 holding.
  • UBS Group first reported a position in Viemed Healthcare in Q4 2019 and has held it in 24 quarters since.
  • UBS Group's Viemed Healthcare position peaked at $2.01M in Q1 2026.
  • 166 funds tracked by Wall St. Rank held Viemed Healthcare as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.